Knight Therapeutics Inc. (TSE:GUD - Get Free Report)'s share price reached a new 52-week high on Wednesday . The stock traded as high as C$5.80 and last traded at C$5.79, with a volume of 74925 shares traded. The stock had previously closed at C$5.57.
Wall Street Analysts Forecast Growth
GUD has been the topic of a number of analyst reports. Raymond James lifted their price target on Knight Therapeutics from C$7.00 to C$7.50 and gave the stock an "outperform" rating in a research note on Wednesday, March 6th. Royal Bank of Canada raised their target price on shares of Knight Therapeutics from C$6.50 to C$7.00 and gave the stock an "outperform" rating in a report on Friday, March 22nd.
Read Our Latest Stock Analysis on GUD
Knight Therapeutics Trading Up 4.5 %
The stock's fifty day moving average price is C$5.43 and its 200 day moving average price is C$5.19. The stock has a market cap of C$588.81 million, a P/E ratio of -36.44, a PEG ratio of -1,013.50 and a beta of 0.49. The company has a current ratio of 3.20, a quick ratio of 1.79 and a debt-to-equity ratio of 9.25.
Insider Buying and Selling at Knight Therapeutics
In other Knight Therapeutics news, insider Sime Armoyan sold 28,200 shares of the firm's stock in a transaction dated Monday, January 22nd. The shares were sold at an average price of C$5.75, for a total transaction of C$162,150.00. 46.45% of the stock is owned by company insiders.
About Knight Therapeutics
(
Get Free Report)
Knight Therapeutics Inc develops, manufactures, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices worldwide. It offers Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Fostamatinib for chronic immune thrombocytopenia; Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Trelstar for advanced prostate cancer; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic cancer; Halaven for metastatic breast cancer and soft tissue sarcoma; and Lenvima for advanced renal cell cancer and for differentiated thyroid cancer and unresectable hepatocellular carcinoma.
Featured Stories
Before you consider Knight Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Knight Therapeutics wasn't on the list.
While Knight Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.
Get This Free Report
